NCT03270748 (GITMO-PHYLOS) is a Phase 2 clinical trial of GvHD prophylaxis in Myeloid Malignancies, sponsored by Gruppo Italiano Trapianto di Midollo Osseo.

Who is sponsoring NCT03270748?

NCT03270748 is sponsored by Gruppo Italiano Trapianto di Midollo Osseo.

What drugs are being tested in NCT03270748?

Interventions in NCT03270748: GvHD prophylaxis.

What condition does NCT03270748 study?

NCT03270748 studies Myeloid Malignancies.

Is NCT03270748 still recruiting?

NCT03270748 is currently completed. Last updated 10 March 2023.

Last reviewed 2023-03-10 · How we verify

NCT03270748: GITMO-PHYLOS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Post Transplant High-Dose Cy as GvHD Prophylaxis in 1 HLA Mismatched Unrelated HSCT for Myeloid Malignancies

Completed Phase 2 Last updated 10 March 2023

What this trial tests

Phase 2 trial testing GvHD prophylaxis in Myeloid Malignancies in 78 participants. Completed in 20 November 2022.

Timeline

15 January 2020

Primary endpoint
20 November 2022

20 November 2022

Quick facts

Lead sponsor	Gruppo Italiano Trapianto di Midollo Osseo
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	78
Start date	15 January 2020
Primary completion	20 November 2022
Estimated completion	20 November 2022
Sites	33 locations across Italy

Drugs / interventions tested

GvHD prophylaxis — full drug profile →

Conditions studied

Myeloid Malignancies — all drugs for Myeloid Malignancies →

Sponsor

Gruppo Italiano Trapianto di Midollo Osseo — full company profile →

Who can join

Adults 18 to 65, any sex, with Myeloid Malignancies. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The experimental treatment consists in the application of a therapeutic strategy with post Transplant High-Dose Cyclophosphamide as GvHD Prophylaxis in Patients Receiving 1-Antigen/Allele HLA Mismatched (7/8 matched) Unrelated Hemopoietic Stem Cell Transplantation for Myeloid Malignancies.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology.
Vanmeerbeek I, Sprooten J, De Ruysscher D, Tejpar S, et al · · 2020 · cited 179× · PMID 32002302 · DOI 10.1080/2162402x.2019.1703449
Impact of anti-thymocyte globulin dose for graft-versus-host disease prophylaxis in allogeneic hematopoietic cell transplantation from matched unrelated donors: a multicenter experience.
Butera S, Cerrano M, Brunello L, Dellacasa CM, et al · · 2021 · cited 19× · PMID 33948721 · DOI 10.1007/s00277-021-04521-z
Posttransplant cyclophosphamide as GVHD prophylaxis in patients receiving mismatched unrelated HCT: the PHYLOS trial.
Raiola AM, Bruno B, Risitano AM, Mosna F, et al · · 2025 · cited 7× · PMID 39928954 · DOI 10.1182/bloodadvances.2024015173

Verify or expand the search:

Other trials of GvHD prophylaxis

Trials testing the same drug.

NCT03434704 — Peripheral Blood Stem Cell Transplantation From Family Haploidentical Donors in Patients With Myelodysplastic Syndrome a · Phase 2 · completed
NCT03963024 — Treosulfan-TMI Conditioning and Rapamycin GvHD Prophylaxis Before Allo-HSCT · Phase 1 · terminated

Other recruiting trials for Myeloid Malignancies

Currently open trials in the same condition.

NCT07396480 — Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic He · Phase 3 · recruiting
NCT06930651 — A Phase I/II Study of CAR.70-Engineered IL15-Transduced Cord Blood-Derived NK Cells With TGF-beta Receptor 2 (TGFBR2) Kn · Phase 1, PHASE2 · recruiting
NCT06668584 — A Phase II Open-label Study of Olutasidenib Post-transplant Maintenance Therapy for Patients With IDH1-mutated Myeloid M · Phase 2 · recruiting
NCT06383572 — Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Che · Phase 1, PHASE2 · recruiting
NCT05796570 — A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combine · Phase 2 · recruiting

Other Gruppo Italiano Trapianto di Midollo Osseo trials

Trials by the same sponsor.

NCT06790680 — GITMO AML/MDS-Relapse Registry Study · completed
NCT04506320 — Novel Drugs After Allo-HSCT in Patients With Multiple Myeloma · completed
NCT04412811 — Prospective Survey of CMV, Herpesviruses Infections and Diseases in Allo-HSCT · completed
NCT04476199 — Venetoclax and Decitabine Assessment in Patients (≥60 - <75 Years) with Newly Diagnosed AML Eligible for Allo-SCT · Phase 2 · active not recruiting
NCT03494959 — Pentaglobin in CRE and PA Neutropenic Infections · Phase 2 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03270748 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Gruppo Italiano Trapianto di Midollo Osseo
Last refreshed: 10 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03270748.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing